Labiotech.eu’s Post

There are more biotechs in the marketplace competing for funds from ever more discerning investors, emphasising the need for more strategic approaches to securing funding. In part one of our two-part whitepaper series, we outline important considerations for biotech seeking funding from VCs, large pharma and other sources. Get advice and insights from industry investors and our biotech experts by downloading our whitepaper here: https://ow.ly/IQF950RrOha

The biopharma sector is currently experiencing a shift and particular interest in artificial intelligence, with a focus on integrating these capabilities into drug discovery and development, and obesity treatments.   In 2023, the biopharma venture capital exit landscape declined from a dollar perspective to US$18.3bn versus US$23.6bn in 2022 but increased from a deal volume perspective to 94 transactions versus 77 in 2022. Exit activity over the last two years is marked by a preference for more mature clinical data compared to the market environment in 2021 which also supported exits for companies with only preliminary clinical data. Notable exits include RayzeBio's US$4.1bn acquisition by Bristol Myers Squibb and Carmot's US$2.9bn acquisition by Roche.

🔬 Biotech News: Strategic Merger Signals Industry Shift TL;DR: Jade Therapeutics (Paragon Biosciences spinout) and Aerovate Therapeutics announce reverse merger, joining forces in respiratory disease therapeutics. Key Industry Impact: • Signals rising M&A activity in biotech sector • Demonstrates how smaller firms can accelerate development through strategic consolidation • Shows alternative path to market vs. traditional development routes Strategic Takeaways for Executives: 1. Consider strategic collaborations to enhance R&D capabilities 2. Monitor emerging firms with complementary technologies 3. Evaluate reverse mergers as efficient public market entry strategy 💡 Executive Action Items: - Review potential synergistic partnerships in your space - Assess M&A opportunities for pipeline expansion - Consider reverse merger vs. traditional IPO pathways What's your take on this trend? Are you seeing similar strategic moves in your biotech segment? Share your insights below. #BiotechNews #MergersAndAcquisitions #BiotechStrategy #PharmaTrends #pharma #biotech #medicinetomarket

Can Europe revive its biopharma innovation leadership? 🇪🇺 While Europe is undoubtedly a prominent biopharma industry it faces challenges, including higher regulatory burdens and escalating R&D costs within Europe, which have pushed some research activities to emerging markets. The European Commission's Ursula von der Leyen recently pledged to put innovation "at the center of Europe's economy" and increase research spending to drive R&D. 🧬 There is so much activity going on across the European biotech at present! Please check the link below for a list of the the top European biotech companies that have received sizeable seed funding in the past year and are directing those funds towards various R&D programs in a range of therapeutic areas. 💰 #Europeanbiotech #biotechfunding #biotechinnovation Quotient Therapeutics | Bioptimus | Relation | ExpressionEdits | Draupnir Bio | Infinitopes | Adcytherix | Commit Biologics | ARTICA Therapeutics | Cumulus Oncology https://lnkd.in/eRGCmrAK

Is the perfect wave of biotech coming our way in 2024? If so, it would bring new and exciting opportunities for VC’s, investors and the entire industry!   Despite the low number of VC investments in Germany in 2023, the life science sector has proven to be resilient.    “We see all the signals that in 2024 significantly more money will flow into biotech,” says Stefan Fischer in his latest column.    TVM Capital Life Science is well positioned to ride the wave: We pursue a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages our strategic relationship with global pharmaceutical firm, Eli Lilly and Company. We also invest in differentiated late clinical-stage therapeutics and commercial-stage medical technologies, as seen with our new portfolio additions myo and Vektor Medical, Inc. 🌟   Dive deeper into what 2024 could hold for the biotech sector by reading the full column on the Plattform Life Sciences website (in German): Die Kunst des Wellenreitens | GoingPublic.de #biotech #medtech #innovation #VentureCapital #investment 

venBio Raises $528M for Fifth Life Sciences Fund - HIT Consultant #FundingNews: venBio raises $528M for fifth life sciences fund #VentureCapital #HealthcareInvestment VenBio, a leading life sciences investment firm, has successfully raised $528 million for its fifth fund, signaling strong investor confidence in the healthcare sector. #InvestmentStrategy: Focused on transformative healthcare technologies #LifeSciences #HealthcareInnovation VenBio's investment strategy revolves around identifying and supporting companies with innovative healthcare technologies that have the potential to transform patient care and outcomes. #PortfolioCompanies: Diverse range of healthcare startups #HealthTech #Biotech The firm's portfolio includes a diverse range of healthcare startups, spanning from digital health to biotech, reflecting VenBio's commitment to supporting innovation across ai.mediformatica.com #lifescience #investment #lifesciences #biopharmaceutical #investing #investments #medical #venturecapital #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/4fzHbyx)

Event Update! Dr. Bodo Alexander Marr is Vice President, Head of M&A/Treasury at MorphoSys will join us as a Keynote Speaker for 14th of November in Frankfurt to our next Capital for Cure summit. MorphoSys AG is a biopharmaceutical company near Munich that was founded in 1992. The company has various antibody, protein and peptide technologies that it uses to research and develop both its own and partnered drug candidates. In February 2024, MorphoSys entered into an agreement to be acquired by Novartis for € 2.7 billion. The forum will provide valuable insights into: -Acquisition vs. In-Licensing: Analyzing the impact of strategic decisions on company growth. -Capital Deployment Strategies: How venture capital and private equity firms navigate biotech investments. -Current M&A Market in Biotech: Understanding the cautious landscape and the role of strategic acquisitions. Further updates will be announced soon. #Biotech #Pharma #Investment Patrick Kraus Mickael Matitia Sebastian Gensior

📊 A new issue of our monthly “𝗙𝗖𝗙 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 & 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗩𝗲𝗻𝘁𝘂𝗿𝗲 𝗖𝗮𝗽𝗶𝘁𝗮𝗹 𝗠𝗼𝗻𝗶𝘁𝗼𝗿 – 𝗘𝘂𝗿𝗼𝗽𝗲” is now available. 🔍 Read the latest financing trends in venture capital in the European life science industry. Our monitor covers Biotech, Pharmaceutical, MedTech, and HealthTech companies. As of the end of March 2024 we identified the following current VC trends in Europe:   - Total Healthcare & Life Sciences funding reached EUR 1,962m - Biotech received 60% of the total investment volume (EUR 1,172m) with oncology being the leading indication (53%) - In March Tubulis GmbH (Germany) secures the highest transaction volume with EUR 128m, followed by Nouscom (Switzerland) with EUR 76m and Mission Therapeutics (United Kingdom) with EUR 51m  - M&G Investments (United Kingdom) is the most active investor (by deal volume), followed by Patient Square Capital (United States) and Rock Springs Capital (United States)   More here: https://lnkd.in/dappZ5WX

Recent success stories in the German biotech industry are setting an end to the muted M&A market, underscoring its innovation power and international attractiveness. Stay tuned for the upcoming EY German Biotech Report 2024, providing key insights on this industry!

Aakha Biologics is a new type of biotech company that values efficiency in the drug discovery process to more rapidly bring high quality therapeutics to patients.   Aakha Biologics is developing biologics that boost the body’s immunosurveillance against tumors and is harnessing multiple advanced antibody discovery platforms to empower its scientists to advance drug candidates from concept to IND-enabling studies. 🚀 We are excited to have Aakha Biologics who listed their innovative drug candidate on Bioneex. Curious to learn more about the innovative drug candidate? Join Bioneex to further explore partnership, in-licensing, and investment opportunities: https://bioneex.com. #immunooncology #immunotherapy #biologicalprotein #antibody #platformtechnology #pharma #biotechnology #biopharma #healthcare #clinicaltrials #innovation #Bioneex